Could live vaccines for viruses such as measles, mumps, and rubella（MMR）also provide protection against COVID-19? That intriguing prospect is the subject of a recently published commentary in mBio.

From the use of novel technologies such as machine learning and CRISPR, to gaining a deeper understanding of the genetic and molecular drivers of cancer, researchers from around the globe shared their progress with the cancer research community on June 22 at the opening plenary session of the American Association for Cancer Research 2020 virtual annual meeting II.

Certain types of RNA viruses may be capable of using host RNA to expand their own genetic repertoire, according to a new study published in Cell on June 18. This mechanism may enable viruses to overcome the limitations of small genomes and more effectively infect host cells.

Adding high-throughput analysis helped speed up downstream process development for drug candidates based on monoclonal antibodies, according to a case study presented June 17 during the BioProcess International Spring Digital Week 2020.

Waters introduced its new Arc high-performance liquid chromatograph（HPLC）system for routine quality control testing in the pharmaceutical, food, academic, and materials markets.

Immunomic Therapeutics（ITI）and Replicate Bioscience have entered into a research and licensing option agreement to combine their technologies to combat infectious diseases and cancers.

Highly targeted and adaptable platforms allow researchers to develop cancer vaccines for a multitude of different cancer types and even create personalized vaccines for individual cancer patients. Researchers from BioNTech and the Wistar Institute shared exciting developments in cancer vaccines in a methods workshop during the American Association for Cancer Research 2020 virtual annual meeting II.

ThermoGenesis has started distribution of the X-Series cell processing platform under the Corning Life Sciences brand, as part of an exclusive global distribution agreement.

Adding high-throughput analysis helped speed up downstream process development for drug candidates based on monoclonal antibodies, according to a case study presented June 17 during the BioProcess International Spring Digital Week 2020.

A new consortium has been formed to increase access to cell-based cancer vaccines by using single-use technology to develop and manufacture dendritic cell cancer vaccines.

The pathway to discovering and developing cancer therapies is not always linear, but well-designed models incorporating smart chemical innovations can provide elegant solutions to treatments for some of the most difficult cancers. Some of these efforts were shared on June 22 during the American Association for Cancer Research 2020 virtual annual meeting II.

Researchers advocated for increased genomic surveillance in younger adult cancer patients with tumors that typically strike later in life, in a study presented at the American Association for Cancer Research 2020 virtual meeting, held June 22 to 24.

From the use of novel technologies such as machine learning and CRISPR, to gaining a deeper understanding of the genetic and molecular drivers of cancer, researchers from around the globe shared their progress with the cancer research community on June 22 at the opening plenary session of the American Association for Cancer Research 2020 virtual annual meeting II.

Frontier Scientific is collaborating with Renibus Therapeutics to develop a COVID-19 therapeutic drug.

Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to build genomics startups.

Lyell Immunopharma and Pact Pharma have formed a strategic partnership to jointly develop and test a next-generation personalized anticancer T-cell therapy against solid tumors.

Critical Path Institute（C-Path）has launched a drug repurposing platform to accelerate the identification of new uses of existing drugs to treat infections, including COVID-19.

Repurpose.AI will collaborate with Scripps Research to develop COVID-19 therapeutics with a focus on drug repurposing.

The U.S. Food and Drug Administration（FDA）has unveiled Project Patient Voice, a new pilot program for communicating patient-reported outcomes from cancer clinical trials.

Healthcare artificial intelligence firm Imagia is partnering with Illumina on a project to further advance the development of precision medicine using genomic and health data.

Ampio Pharmaceuticals will begin a phase I clinical trial to evaluate its Ampion drug candidate for treatment of COVID-19 patients who are on supplemental oxygen.

Certain types of RNA viruses may be capable of using host RNA to expand their own genetic repertoire, according to a new study published in Cell on June 18. This mechanism may enable viruses to overcome the limitations of small genomes and more effectively infect host cells.

Illumina has acquired BlueBee, a Dutch genomics analysis software firm that originated as a spinoff from Delft University of Technology, in an effort to boost its next-generation sequencing（NGS）capability.

Could live vaccines for viruses such as measles, mumps, and rubella（MMR）also provide protection against COVID-19? That intriguing prospect is the subject of a recently published commentary in mBio.

Therapeutic Solutions plans to develop its clinical stage cancer immunotherapy treatment StemVacs for treatment of COVID-19 patients.

Codagenix has successfully synthesized a live-attenuated vaccine candidate for COVID-19 called CDX-005.

Alpine Immune Sciences and AbbVie have entered an exclusive worldwide option and license agreement for ALPN-101, a dual cluster of differentiation 28 and inducible T-cell co-stimulator immune antagonist.